Recombinant Human CDK8 Protein (Glu21-Asp392), N-His tagged

• Cat.No.: CDK8-1272H
• Product Overview: Recombinant Human CDK8 (Glu21-Asp392) fused with the N-His tag was expressed in E. coli.

Specification

• Source: E. coli
• Species: Human
• Tag: N-His
• Form: Lyophilized powder/frozen liquid
• Molecular Mass: 45.33 kDa
• Protein Length: Glu21-Asp392
• Purity: >90% as determined by SDS-PAGE.
• Notes: For research use only.
• Storage: Use a manual defrost freezer and avoid repeated freeze thaw cycles.
  Store at 2 to 8 centigrade for one week.
  Store at -20 to -80 centigrade for twelve months from the date of receipt.
• Storage Buffer: 0.01M PBS, pH 7.4, 0.02% NLS
• Reconstitution: Reconstitute in sterile water for a stock solution.
• Shipping: They are shipped out with dry ice/blue ice unless customers require otherwise.

Gene Information

• Gene Name: CDK8 cyclin-dependent kinase 8 [ Homo sapiens (human) ]
• Official Symbol: CDK8
• Synonyms: CDK8; cyclin-dependent kinase 8; K35; protein kinase K35; CDK8 protein kinase; mediator complex subunit CDK8; cell division protein kinase 8; mediator of RNA polymerase II transcription subunit CDK8; MGC126074; MGC126075
• Gene ID: 1024
• mRNA Refseq: NM_001260
• Protein Refseq: NP_001251
• MIM: 603184
• UniProt ID: P49336

Reviews

03/05/2020

The CDK8 protein stands as a remarkable solution that exemplifies exceptional quality and meets all my experimental requirements.

08/03/2019

I am confident that the CDK8 protein will unlock vital insights into cellular processes, propelling my scientific investigations to new heights.

10/01/2017

Its impressive purity and functional characteristics make it an ideal choice for my research endeavors, ensuring reliable and impactful results.

Q&As

Is CDK8 exclusively associated with cancer, or does it have physiological roles in normal cellular functions?

CDK8 plays essential roles in normal cellular functions, including development and tissue homeostasis. Its dysregulation, however, is implicated in cancer.

Can CDK8 inhibitors be used in combination with other cancer treatments, and if so, what are the potential benefits?

Combination therapies involving CDK8 inhibitors are being explored to enhance treatment outcomes and reduce the likelihood of resistance, providing a more comprehensive approach to cancer management.

How does CDK8 inhibition affect the cell cycle, and why is this significant in cancer therapy?

CDK8 inhibition can disrupt the cell cycle, slowing down or halting the uncontrolled cell division characteristic of cancer cells, making it a potential therapeutic strategy.

How does CDK8 influence the immune response in the tumor microenvironment?

CDK8 can modulate the expression of genes involved in immune response. Understanding its role in the tumor microenvironment may lead to novel immunotherapeutic strategies.

Are there ongoing clinical trials investigating the efficacy of CDK8 inhibitors in cancer patients?

Yes, several clinical trials are underway to assess the safety and effectiveness of CDK8 inhibitors as a targeted therapy for different types of cancer.